

IAP12 Rec'd PCT/PTO 25 APR 2007

Attorney Docket No. 9237-14

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Irene Kazhdan  
Serial No.: 10/578,445  
Filed: May 4, 2006

Confirmation No.: 2107  
Group Art Unit: 1632

For: **METHODS AND COMPOSITIONS FOR COMBINATORIAL APPROACHES TO CANCER  
GENE THERAPY**

Date: April 25, 2007

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)**

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the amendment by the U.S. Patent and Trademark Office to 37 C.F.R. § 1.98(a)(2)(ii) effective October 21, 2004.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP.

Respectfully submitted,

*Mary L. Miller*

Mary L. Miller  
Registration No. 39,303

Myers Bigel Sibley & Sajovec, P.A.  
P. O. Box 37428  
Raleigh, North Carolina 27627  
Telephone: (919) 854-1400  
Facsimile: (919) 854-1401  
Customer No. 20792

**CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10**

"Express Mail" mailing label number: EV887527850US

Date of Deposit: April 25, 2007

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*Tracy Wallace*  
Tracy Wallace

Substitute form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/578,445
				Filing Date	May 5, 2006
				First Named Inventor	Irene Kazhdan
				Group Art Unit	1632
				Examiner Name	Unknown
(use as many sheets as necessary)				Attorney Docket Number	9237-14
Sheet	1	Of	1		

U.S. PATENTS AND PATENT PUBLICATIONS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	1.	US 2003/0082722	A1	Fang	05/01/2003

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office	Number	Kind Code (if known)			

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	2.	Copy of International Search Report for PCT/US04/35643, mailed June 20, 2005	
	3.	Fukazawa et al. "Adenoviral Bid Overexpression Induces Caspase-dependent Cleavage of Truncated Bid and p53-independent Apoptosis in Human Non-small Cell Lung Cancers" <i>The Journal of Biological Chemistry</i> 278(28):25428-25434 (2003).	
	4.	Futami et al. "Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2" <i>Nucleic Acids Research Supplement</i> 2:251-252 (2002).	
	5.	Kazhdan et al. "Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)" <i>Cancer Gene Therapy</i> 11:691-698 (2004)	
	6.	Kichler et al. "Histidine-rich amphipathic peptide antibiotics promote efficient delivery of DNA into mammalian cells" <i>PNAS</i> 100(4):1564-1568 (2003)	
	7.	Morris et al. "A novel potent strategy for gene delivery using a single peptide vector as a carrier" <i>Nucleic Acids Research</i> 27(17):3510-3517 (1999)	
	8.	Morris et al. "A new peptide vector for efficient delivery of oligonucleotides into mammalian cells" <i>Nucleic Acids Research</i> 25(14):2730-2736 (1997)	
	9.	Rudolph et al. "Oligomers of the Arginine-rich Motif of the HIV-1 TAT Protein Are Capable of Transferring Plasmid DNA into Cells" <i>The Journal of Biological Chemistry</i> 278(13):11411-11418 (2003)	
	10.	Simeoni et al. "Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells" <i>Nucleic Acids Research</i> 31(11):2717-2724 (2003)	
	11.	Song et al. "Adenovirus-mediated Suicide Gene Therapy Using the Human Telomerase Catalytic Subunit (hTERT) Gene Promoter Induced Apoptosis of Ovarian Cancer Cell Line" <i>Biosci. Biotechnol. Biochem.</i> 67(11):2344-2350 (2003).	
	12.	Sun et al. "Overexpression of Bcl2 Blocks TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis in Human Lung Cancer Cells" <i>Biochemical and Biophysical Research Communications</i> 280:788-797 (2001).	
	13.	Dorovsky et al. "Targeted gene therapy for breast cancer" Symposium on Advances in Cell Signaling in Cancer Therapy, November 9, 2003, hosted by the Department of Medicine, Divisions of Medical Oncology and Hematology, University of Texas Health Science Center at San Antonio (Abstract)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.